ライフサイエンスコーパス: catalytic antibody

1 r Arg90Cit and Glu52Ala mutants, and the 1F7 catalytic antibody.

2 Cope rearrangement compared to the germ line catalytic antibody.

3 tes in conjunction with a unique broad-scope catalytic antibody.

4 state stabilization in the evolution of this catalytic antibody.

5 h combines anti-TrkB antibody with the h38C2 catalytic antibody.

6 r effect on reactions promoted by engineered catalytic antibodies.

7 erate the germline and affinity-matured AZ28 catalytic antibodies.

8 splay to generate a panel of closely related catalytic antibodies.

9 low the procurement of a wide range of novel catalytic antibodies.

10 The catalytic antibody 13G5 catalyzes a disfavored exo Diels

11 Catalytic antibody 15A10 hydrolyzes the benzoyl ester of

12 antigen binding loops from a murine-derived catalytic antibody, 17E8, onto a human antibody framewor

13 steroids to antibody DB3 and of a hapten to catalytic antibody 1E9 are computed and compared to expe

14 ight into the evolution of the redox active, catalytic antibody 28B4, the germline genes used by the

15 graphic structure of the Fab fragment of the catalytic antibody, 29G11, complexed with an (S)-norleuc

16 ivities (% ee) derived from an enamine-based catalytic antibody 33F12 and a chiral organocatalyst.

17 Furthermore, this is the first example of catalytic antibody 38C2 displaying regioselectivity on a

18 The catalytic antibody 38C2 only reacted with surface-expose

19 In addition, catalytic antibody 38C2 was able to selectively differen

20 tivation using the prohormone insulin(D) and catalytic antibody 38C2 with potential therapeutic appli

21 The crystal structure of the esterase catalytic antibody 48G7 has been determined in the prese

22 posure to the bacterium and reduction of the catalytic antibody activity following infection.

23 to the substrate (the compound on which the catalytic antibody acts) lead to dramatic differences in

24 With the ubiquity of catalytic antibodies against glycans virtually unknown,

25 Here we demonstrate a novel CocH form, a catalytic antibody analog, which is a fragment crystalli

26 eve this goal: namely, computational design, catalytic antibodies and mRNA display.

27 the formation of a covalent bond between the catalytic antibody and the hapten, as well as the tether

28 fficiency of natural enzymes evolve, but the catalytic antibodies are much more accepting of a wide r

29 Catalytic and non-catalytic antibodies are studied in this context of acti

30 Sequence analysis of the four catalytic antibodies, as well as four inactive antibodie

31 tic receptor fulfils a role reminiscent of a catalytic antibody by stabilizing the planar transition

32 Catalytic antibodies (CAbs) occur naturally in healthy i

33 Catalytic antibodies capable of oxidatively degrading th

34 Peptide bond-hydrolyzing catalytic antibodies (catabodies) could degrade toxic pr

35 assical immunization methods do not generate catalytic antibodies (catabodies), but recent findings s

36 In this approach, a catalytic antibody catalyzes the covalent conjugation of

37 turnover of a photochemical reaction using a catalytic antibody could be observed.

38 inogen activator inhibitor, addition of anti-catalytic antibodies directed against urokinase plasmino

39 of four related Fab fragments of a family of catalytic antibodies displaying differential levels of e

40 An array of substances, including catalytic antibodies, DNA, RNA, antigens, live bacterial

41 by antibodies 13G5 and 4D5 as well as other catalytic antibodies elicited in the same immunizations

42 Activity of catalytic antibodies for hydrolysis of enol ethers is de

43 g the first example of a naturally occurring catalytic antibody for polysaccharides.

44 s indicate the power of initial selection of catalytic antibodies from a biased antibody library in b

45 The existence of catalytic antibodies has been known for decades.

46 The forte of catalytic antibodies has resided in the control of the g

47 Catalytic antibodies have been shown to have chemoselect

48 However, few catalytic antibodies have efficiencies that approach tho

49 Catalytic antibodies have emerged as being without peer

50 Catalytic antibodies have shown great promise for cataly

51 Many naturally occurring catalytic antibodies have since been isolated from human

52 This study demonstrates the utility of catalytic antibodies in examining the relationship betwe

53 Catalytic antibodies induced by GNT-KLH were also shown

54 Although the discovery of catalytic antibodies initially aroused great interest be

55 One of the fascinations of catalytic antibodies is the possibility of harnessing th

56 t catalysts for related reactions, including catalytic antibodies (kcat/kuncat=10(6) to 10(8)) and an

57 pplicable in repetitive format for screening catalytic antibody libraries.

58 To provide a new approach, the high-activity catalytic antibody mAb 15A10 was elicited using a transi

59 aine hydrolysis catalyzed by an anti-cocaine catalytic antibody, mAb15A10, were studied by using a no

60 report a chemotherapeutic strategy based on catalytic antibody-mediated prodrug activation.

61 g the chemistry of the well studied aldolase catalytic antibodies of which mAb 38C2 is a member.

62 Whilst catalytic antibodies, on average, have marginally higher

63 Re-engineered natural enzymes and catalytic antibodies, possessing tailored binding pocket

64 cellular fibrinogen-binding protein (Efb) by catalytic antibodies produced with no exposure to the ba

65 erent from that induced by the antibody; the catalytic antibody produces a distortion which is simila

66 and structural data are consistent with the catalytic antibody providing oxyanion stabilization as i

67 cloning and kinetic analysis of a family of catalytic antibodies raised against a common transition

68 In this regard, the presence of catalytic antibodies recognizing host antigens has been

69 e current state of anti-cocaine vaccines and catalytic antibody research to aid in the fight against

70 is one of the most promising achievements of catalytic antibody research.

71 nstrate that exposing C. neoformans cells to catalytic antibodies results in changes in complement de

72 n as one of the few systems where the mature catalytic antibody shows a negative correlation between

73 une system and reveals that the evolution of catalytic antibodies significantly predates their ration

74 putative site was found in 14 of 63 (22.2%) catalytic antibody structures and 119 of 1602 (7.4%) ant

75 these structures are the highest resolution catalytic antibody structures to date and provide insigh

76 within the hydrophobic environments of this catalytic antibody than speculated for natural aldolase

77 This process yielded aldolase catalytic antibodies that approximated the rate accelera

78 n criteria of the immune system are changed, catalytic antibodies that have the efficiency of natural

79 IgG catalytic antibodies that specifically hydrolyzed Efb vi

80 A powerful application resulted in catalytic antibodies that use an enamine mechanism akin

81 body 38C2 is the prototype of a new class of catalytic antibodies that were generated by reactive imm

82 the key lessons learned from the science of catalytic antibodies--that binding energy can be convert

83 Among catalytic antibodies, the well-characterized antibody 43

84 arginally higher active site burial than non-catalytic antibodies, these values are generally smaller

85 defense function for constitutively produced catalytic antibodies to a putative superantigenic site o

86 Furthermore, naturally occurring catalytic antibodies to microbial determinants have been

87 s can be readily used to optimize binding of catalytic antibodies to transition-state analogs, and wh

88 This is an inaugural report of a catalytic antibody utilizing dendrimers as substrates an

89 The catalytic antibodies were prepared by reactive immunizat

90 ese prodrugs are selectively unmasked by the catalytic antibody when it is applied at therapeutically

91 nues for the improvement of first generation catalytic antibodies with chorismate mutase activity.

92 yield a functional single-chain version of a catalytic antibody with chorismate mutase activity.

93 rationally designed cocaine antagonist and a catalytic antibody with potential for medicinal use.